No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
GPCR250117C47500
- 0.57
- +0.27+90.00%
15min DelayClose Dec 20 16:00 ET
0.65High0.57Low
0.65Open0.30Pre Close50 Volume71 Open Interest47.50Strike Price3.05KTurnover147.91%IV72.29%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.57Extrinsic Value100Contract SizeAmericanOptions Type0.1236Delta0.0187Gamma48.95Leverage Ratio-0.0436Theta0.0020Rho6.05Eff Leverage0.0151Vega
Intraday
- 5D
- Daily
News
H.C. Wainwright Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $80
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Prothena (PRTA) and CVS Health (CVS)
Promising Potential of Structure Therapeutics' ACCG-2671 Drives Buy Rating
Buy Rating for Structure Therapeutics, Inc. Driven by Innovative Drug Development and Promising Obesity Treatment Platform
Express News | Shares of Viking Therapeutics up 4.2%, Amgen up 1%
The weight loss effect of the new drug was below expectations, and Novo-Nordisk A/S saw its stock plummet by 28% in Pre-Market Trading, while competitor Eli Lilly and Co surged over 12%.
The experimental results show that patients who received subcutaneous injections of CagriSema lost an average of 22.7% of their weight after 68 weeks. If volunteers who dropped out of the trial are included, the average weight loss effect decreases to 20.4%, both below the company's previous expectation of 25%.